EICOSAPENTAENOIC ACID IN TREATMENT‐RESISTANT DEPRESSION ASSOCIATED WITH SYMPTOM REMISSION, STRUCTURAL BRAIN CHANGES AND REDUCED NEURONAL PHOSPHOLIPID TURNOVER
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
SUMMARY: The n‐3 essential fatty acid eicosapentaenoic acid (EPA) was added to the conventional antidepressant treatment of a treatment‐resistant severely depressed and suicidal male patient with a seven‐year history of unremitting depressive symptoms. The niacin skin flush test and cerebral magnetic resonance scanning were carried out at baseline and nine months later. The addition of ethyl‐EPA led to a dramatic and sustained clinical improvement in all the symptoms of depression, including a cessation of previously unremitting severe suicidal ideation, within one month. Symptoms of social phobia also improved dramatically. During the nine‐month period the volumetric niacin response increased by 30%, the relative concentration of cerebral phosphomonesters increased by 53%, and the ratio of cerebral phosphomonesters to phosphodiesters increased by 79%, indicating reduced neuronal phospholipid turnover. Registered difference images showed that the EPA treatment was accompanied by structural brain changes including, in particular, a reduction in the lateral ventricular volume.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Cited by
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
“This compound also induced neurobiological changes, such as a 30% increase in the volumetric niacin response, a 53% increase in the relative concentration of cerebral phosphomonoesters, a 79% increase in the ratio of cerebral phosphomonoesters to phosphodiesters, and a reduction in the lateral ventricular volume of th…”
Meta-Analysis of the Effects of Eicosapentaenoic Acid (EPA) in Clinical Trials in Depression
Sublette, M. E., Ellis, S. P., Geant, A. L., & Mann, J. J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06634 · Cited by 417
Efficacy of omega-3 PUFAs in depression: A meta-analysis
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0515-5 · Cited by 404
Martins, J. G. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719785 · Cited by 358
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329
Self-citation
Metadata
- Authors
- Puri, B., Counsell, S., Hamilton, G., Richardson, A., & Horrobin, D.
- Venue
- International Journal of Clinical Practice
- Publisher
- Wiley
- Published
- 2001-10
- Volume
- 55
- Issue
- 8
- Pages
- 560-563
- ISSN
- 1368-5031 (ISSN-L)
- 1742-1241
- OpenAlex
- W68713625
- Cited by
- 110
- References
- 3
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EICOSAPENTAENOIC ACID IN TREATMENT‐RESISTANT DEPRESSION ASSOCIATED WITH SYMPTOM REMISSION, STRUCTURAL BRAIN CHANGES AND REDUCED NEURONAL PHOSPHOLIPID TURNOVER. https://app.cochat.ai/papers/10.1111/j.1742-1241.2001.tb11122.x
- The paper
- Puri, B., Counsell, S., Hamilton, G., Richardson, A., & Horrobin, D. (2001). EICOSAPENTAENOIC ACID IN TREATMENT‐RESISTANT DEPRESSION ASSOCIATED WITH SYMPTOM REMISSION, STRUCTURAL BRAIN CHANGES AND REDUCED NEURONAL PHOSPHOLIPID TURNOVER. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2001.tb11122.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.